Imagine a future where a simple urine test can detect deadly diseases before they get out of control. A future when diseases can be intercepted and people don’t become patients. At Glympse Bio, we are working to turn this vision into a reality. Take a glimpse into that future, where we are taking a glimpse inside the body.
By pioneering the latest advancements in science, engineering, and medicine, we have created a new class of activity sensors that query the body and report back clinically-relevant information. Our approach is designed to be safe, simple, fast, and noninvasive, providing detailed insights into disease activity in real-time including its onset, stage, and response to treatments.
Our precisely-engineered activity sensors can be customized to report on diseases, tissues, cells, and broad biological targets. Disease sites are tuned by customizing routes of delivery (e.g. intravenous, inhaled, subcutaneous, etc) and produce readouts compatible with a broad range of multiplexed analytical platforms (e.g., Mass Spectrometry, ELISA, etc).
Information-rich results provide unique clinical insights into disease activity of biological targets for single patients or populations. At the earliest stages, long before other diagnostic methods are able, we aim to gain a glimpse into the stage and progression of important, complex diseases, such as cancer, fibrosis, inflammation, and infections.
Our activity sensors are administered to patients and tailor-made to query the activity of key biological targets such as proteases – a class of enzymes that drive critical disease pathways. We are applying sophisticated machine learning algorithms to develop a proprietary, whole-genome database of enzymes and sensors capable of targeting all clinically-relevant proteases. Our technology platform is extendable to multifunctional enzymes including kinases, glycases, and lipases.
Our lead program is Non-Alcoholic Steatohepatitis (NASH), estimated to impact 16 million people in the U.S. and over 100 million worldwide. Our development pipeline features programs in liver and lung diseases (representing over $5 billion in total addressable markets) with preclinical validation in 10+ additional diseases.
Glympse has a creative business model that blends the best of a diagnostic development and regulatory pathway, therapeutics go-to-market model, and a biology-rich data engine.
Sangeeta Bhatia leverages 'tiny technologies' of miniaturization to yield inventions with new applications in tissue regeneration, stem cell differentiation, medical diagnostics, predictive toxicology and drug delivery.
Founded in 2015, Glympse Bio is an MIT spin-out from the laboratory of renowned bioengineer, Dr. Sangeeta Bhatia. Glympse Bio is currently located at the LabCentral incubator in Cambridge, MA.
Our team is committed to enhancing our understanding of human disease. Our goal is to better serve the needs of patients, clinicians, researchers, drug developers, and payors.
President & CEO
Caroline is a biopharmaceutical executive with over 20 years of experience successfully leading diverse, empowered and integrated teams. She has broad experience integrating science, business and the clinic to deliver differentiated value to patients. Most recently, she was Vice President, Head R&D Strategy and Planning at Bristol-Myers Squibb where she led portfolio strategy and operations. This included shaping BMS’s strategy and portfolio to deliver strong competitive positioning in immuno-oncology, immunoscience, fibrosis and cardiovascular, together with a new fit-for-purpose operating model. Her earlier career spanned leadership roles in commercial, market access, regulatory and drug development. An organic chemist by training, Caroline studied as an undergraduate and postgraduate at Imperial College, London.
Co-Founder
Sangeeta trained as a bioengineer and physician at Brown, MIT, Harvard, and MGH and currently heads the Cancer Nanomedicine Center at the Koch Institute at MIT. Her lab leverages miniaturization tools to impact human health, enabling new methods to model and regenerate tissue, diagnose and monitor disease, and deliver drugs and nucleic acid therapies. Bhatia is an elected member of the National Academy of Science, National Academy of Engineering, and National Academy of Invention, and the recipient of the Heinz Medal and the Lemelson-MIT prize. She currently serves as a Director at Vertex Pharmaceuticals and a Trustee at Brown University. Fun facts about Sangeeta: she likes yoga, all things coffee, good books, travel, being with friends and family and crafting with her daughters. Thanksgiving is her favorite holiday.
Co-Founder & Chief Scientific Officer
Gabe trained as a bioengineer at UC Berkeley, Caltech and MIT, and currently is a Principal Investigator at the Lab for Synthetic Immunity at Georgia Tech and Emory School of Medicine. His research merges engineering approaches with discoveries in immunology to advance human health. He and his team have developed innovative technologies that shape broad applications in biomedical diagnostics and cell-based therapies, and impact frontier challenges in cancer, transplant medicine and infectious diseases. When he is not in the lab or classroom, Gabe can be found hiking, playing guitar, or at the gym training for his favorite show: American Ninja Warrior.
Chief Development Officer
Eric trained as a bioengineer at Brown and Rutgers. Prior to Glympse, Eric held leadership roles at Acusphere and Epirus Biopharmaceuticals in product development, business development, technical operations, and program management. At Glympse, Eric leads all development activities including overseeing day-to-day operations. When he’s not in charge of all things Glympse, Eric loves to ski and tend to his cichlid fish tank. He also likes to let his kids take over just to see what they’ll do...and he’s frequently impressed by what they come up with.
Chief Business Officer
Roopom studied biology and economics at MIT and Harvard, and at Glympse is focused on strategy, financing, partnering, and intellectual property. Most recently, Roopom was the President & CEO at RainDance Technologies (acquired by BioRad Labs). Previously, Roopom worked at Leerink Swann, McKinsey, and Goldman Sachs to complete 70+ private/public financings and M&A transactions. In his former science life, Roopom worked in cancer genomics at the Dana Farber, Whitehead Institute and MGH. Roopom is an avid tennis player and channels his inner adrenaline junkie into mountain biking as well as nature photography.
Chairman of the Board
Stan Lapidus is an inventor/entrepreneur who serves on a number of healthcare and medical technology boards. He’s been founding CEO of four medical technology companies including Cytyc Corp (modern pap smear), Exact Sciences (non-invasive screening for colorectal cancer), Helicos (single molecule DNA sequencing) and SynapDx (early detection of autism).
Stan holds 36 patents, primarily in methods for early detection of cancer. He was elected as a Fellow of the American Institute of Medical and Biological Engineering in 2014 for his work on the early detection of cancer.
Stan graduated from Cooper Union in New York City with a BS degree in electrical engineering.
Board Director
Amy is a highly respected leader in biotech and pharma. She joined Polaris Partners in 2014 and brings her commercial expertise to the startup biotech community. She is currently Partner of the LS Polaris Innovation Fund and is the active CEO and Co-Founder of Lyndra. She is also a Director of Quentis and Kallyope. Previously, Amy was General Counsel at Pfizer, President of Pfizer Nutrition, and President of Pfizer Consumer Healthcare. She has received numerous awards including Xconomy’s 2017 Newcomer Award, Scientific American’s 2015 Worldview 100 List, Fierce Biotech’s 2014 Top 15 Women in Biotech, and Fortune Magazine’s 2013 50 Most Powerful Women in Business. She is a Senior Lecturer at Harvard Business School and serves on the Boards of Alnylam, Blue Buffalo, Ironwood, and the Whitehead Institute. She was Phi Beta Kappa at Wesleyan and earned her J.D. from Yale Law School.
Board Director
Theresia co-founded Aspect Ventures, a leading early-stage venture firm with a unique focus on bridging the funding gap between angels and the larger multi-stage VC platforms through collaboration and diversity. She led the firm’s early investments in Cato Networks, Deserve, Exabeam, ForeScout (FSCT), The Muse, Crew and ShieldX. Prior to launching Aspect, Theresia was a Managing General Partner at Accel where she championed many successful companies through IPOs or acquisitions including Imperva (IMPV), Trulia (TRLA), LearnVest (Northwestern Mutual), Jasper Design (CDNS) and Kosmix (WMT). Earlier, she worked at Release Software, Bain & Company and Silicon Graphics. Theresia holds an ScB in Engineering magna cum laude from Brown University (where she serves as Treasurer of Brown’s Corporation board) and an MBA from Stanford. Theresia has been honored seven times as a member of Forbes’ Midas List of top venture capitalists.
Board Director
Robert S. Langer is one of 10 Institute Professors at MIT; being an Institute Professor is the highest honor that can be awarded to a faculty member. Dr. Langer has written more than 1,400 articles. He also has over 1,300 issued and pending patents worldwide. Dr. Langer’s patents have been licensed or sublicensed to over 350 pharmaceutical, chemical, biotechnology and medical device companies. He is the most cited engineer in history (h-index 262 with over 275,000 citations according to Google Scholar).
Jeffrey Arnold, Ph.D.
CEO, Arnold Strategies
Scott Friedman, M.D.
Chief, Division of Liver Diseases, Icahn School of Medicine, Mt. Sinai
Rohit Loomba, M.D., MHSc.
Director of Hepatology; Vice Chief, Division of Gastroenterology, UCSD
Arun Sanyal, M.D.
Professor, Division of Gastroenterology, Hepatology & Nutrition, VCU
Gyongzi Szabo, M.D., Ph.D., FAASLD
Vice Chair of Research, Dept of Medicine, UMass Medical School
We are a dynamic and high energy team that believes anything is possible with great science and great people. We are all committed to solving global health problems, and unapologetic about our grand aspirations to do so. We are creative, nimble, problem-solvers who equally embrace learning and smart risk-taking. We have been told we are ‘impatient optimists’, a badge we wear proudly to translate vision into action. We also care for one another and are committed to each others’ success.
If you fit the Glympse Bio profile, come partner with us! We are actively building our team and recruiting industry partners to our cause.
Glympse Bio has a discovery engine and product platform that is changing the paradigm for drug development and discovery. We are already establishing collaborations with Pharma for predicting or monitoring drug response in clinical trials or for launched drugs.
Glympse Bio offers a disruptive approach to developing and delivering activity sensors that have superior attributes to the endogenous biomarkers available in nature. We can tune our in vivo sensors to achieve a desired sensitivity, specificity, delivery, and readout. Best of all, our platform comes packaged in a favorable device regulatory pathway and drug reimbursement model.
We have a customizable and scalable technology platform that can predict and monitor patient responses to therapy, to ensure that the right patient receives and responds to the right treatment.
We are looking for distinctive people to join our fabulous team. And we are growing rapidly!
Preview our feed below.
We were in stealth mode…not anymore!
See what people are saying.
Shout outs to our team.
